The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC).
Malcolm J. Moore
Consultant or Advisory Role - Celgene (U)
Research Funding - Celgene
Daniel D. Von Hoff
Consultant or Advisory Role - Celgene (U)
Honoraria - Celgene
Research Funding - Celgene
Thomas J. Ervin
Research Funding - Celgene
Francis P. Arena
Research Funding - Celgene
E. Gabriela Chiorean
Research Funding - Celgene
Jeffrey R. Infante
No relevant relationships to disclose
Jeremy K. Hon
No relevant relationships to disclose
Mikhail Yu Biakhov
Research Funding - Celgene
Sunil R. Hingorani
No relevant relationships to disclose
Vinod Ganju
No relevant relationships to disclose
Colin D. Weekes
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Werner Scheithauer
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Ramesh K. Ramanathan
Consultant or Advisory Role - Celgene (U)
Honoraria - Abraxis BioScience
Research Funding - Celgene
Josep Tabernero
Consultant or Advisory Role - Celgene
David Goldstein
Consultant or Advisory Role - Celgene (U)
Research Funding - Celgene
Xinyu Wei
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Alfredo Romano
Employment or Leadership Position - Celgene
Stock Ownership - Celgene